In a small health centre in Papua New Guinea's Highlands, a midwife reaches for the oxytocin vial during a postpartum hemorrhage. The shelf is empty. She has no stock count to warn her; the last audit was months ago. She grabs misoprostol tablets from a drawer, but they are past their expiry date. She begins bimanual compression, a technique she learned as a last resort. This scene repeats across the country, where maternal mortality remains among the highest in the Pacific region.

When the Oxytocin Shelf Runs Empty

Postpartum hemorrhage (PPH) is the leading direct cause of maternal death in Papua New Guinea, accounting for roughly one-third of maternal deaths. The World Health Organization recommends oxytocin as the first-line uterotonic, citing a 60% reduction in PPH risk when given immediately after delivery. Yet in many rural clinics, oxytocin is simply not available.

A 2023 survey of health facilities in four provinces found that 40% lacked oxytocin on the day of the visit. Stockouts typically last weeks, and no formal stock-count system exists for emergency drugs in most clinics. Midwives rely on misoprostol—less effective but more heat-stable—or controlled cord traction alone. Some use ergometrine when available, despite its contraindications in hypertension.

The absence of oxytocin is not a supply failure alone. It reflects a deeper disconnect between national procurement and local distribution. Central warehouses may have stocks, but road conditions, fuel costs, and poor cold-chain infrastructure mean vials degrade before arrival. Midwives often discover the shortage only when an emergency begins.

To understand the scale, consider that Papua New Guinea has over 600 rural health facilities, many accessible only by foot or small aircraft. The national cold chain relies on kerosene refrigerators that frequently break down. A 2022 assessment by the World Bank found that only about 30% of rural facilities had functional cold chain equipment for storing oxytocin. In the remaining 70%, vials are kept at room temperature, losing potency within days. This means even when oxytocin is present on paper, its effectiveness is uncertain.

Stockout patterns vary by region. In coastal provinces like Milne Bay, stockouts are more seasonal, tied to shipping schedules. In the Highlands, road closures during the wet season can cut off supply for months. A midwife in Enga Province reported that her clinic received oxytocin only twice in the previous year. Each delivery lasted a few weeks, leaving gaps of months in between. She learned to ration the drug for the most severe cases, a practice not taught in any curriculum.

The Evidence Gap Between Guidelines and Ground Reality

Systematic reviews confirm that oxytocin reduces PPH risk by roughly 60% when given within one minute of birth. But that effectiveness drops to zero when the vial is empty or the cold chain broken. Misoprostol, while recommended as an alternative, is less effective in preventing severe hemorrhage and carries more side effects like shivering and fever.

Studies from Papua New Guinea show that misoprostol is available in about 70% of facilities, but its use is often delayed because midwives wait for oxytocin to appear. A 2022 study in the Papua New Guinea Medical Journal found that only 55% of PPH cases received any uterotonic within 15 minutes, the recommended window. The rest relied on uterine massage and fluid resuscitation.

Some clinicians argue that misoprostol should be promoted as first-line in remote settings, given its heat stability and oral route. Others worry that downgrading oxytocin would worsen outcomes in facilities where cold chain could be fixed. The debate remains unresolved, and midwives bear the burden of deciding in real time.

Data from neighbouring countries offer a cautionary tale. In the Solomon Islands, a 2018 policy shift to misoprostol as first-line for home births reduced PPH deaths by an estimated 30%, but also led to a rise in referrals for retained placenta—a known risk with misoprostol. In Papua New Guinea, where transport is even more challenging, such trade-offs need careful consideration. A 2020 modelling study suggested that if misoprostol replaced oxytocin in all rural facilities, severe PPH cases might increase by 10–15% due to lower efficacy, but deaths could still drop because more women would receive some uterotonic. The net effect depends on coverage rates and transport times.

Another layer of complexity is the quality of misoprostol itself. A 2021 study of drug quality in Papua New Guinea found that about 15% of misoprostol samples failed dissolution testing, meaning the tablets might not dissolve properly in the body. Counterfeit or substandard drugs are an under-recognised problem. Midwives have no way to test potency at the point of care.

Training That Ignores the Drug Supply

Pre-service midwifery curricula in Papua New Guinea teach oxytocin as first-line management for PPH, with detailed protocols for dosing and administration. In-service drills often simulate ideal conditions: a fully stocked drug tray, a functioning refrigerator, and a team ready to assist. But no module teaches what to do when the drug is simply not there.

The recent WHO Bundibugyo trial in the Democratic Republic of the Congo highlights the importance of logistics in emergency care. That trial, testing treatments for a viral hemorrhagic fever, required meticulous stock management and real-time resupply. In Papua New Guinea, similar logistical discipline is absent for a far more common emergency.

Midwives learn bimanual compression and aortic compression as last-resort measures, but these are rarely practiced in drills. A 2021 study found that only 30% of midwives in rural facilities had performed a simulated PPH drill in the past year. When asked about managing PPH without uterotonics, most said they would transfer the patient—a decision that can take hours on unpaved roads.

Training gaps extend beyond PPH. A 2023 curriculum review by the Papua New Guinea National Department of Health found that only two of the country's 12 midwifery schools included a module on supply chain management. Students are not taught how to check expiry dates, maintain cold chain logs, or report stockouts to supervisors. As a result, midwives enter the workforce unprepared for the most common barrier to care.

Some organisations are trying to fill the gap. The non-profit Mercy Ships has run PPH simulation workshops in rural hospitals, including scenarios where the drug tray is empty. These workshops are popular but reach only a few hundred midwives per year. The government's own Helping Babies Survive and Helping Mothers Survive programmes include some drug-absent scenarios, but they are not mandatory and funding is inconsistent.

A counter-argument from some educators is that teaching drug-absent management might lower expectations for supply chain improvement. They worry that if midwives become too skilled at improvising, the government will have less incentive to fix procurement. But this argument ignores the reality that midwives already improvise, often poorly. Formal training would at least ensure they do so safely.

Burnout from Constant Improvisation

Repeated PPH emergencies without the expected drugs take a psychological toll. Midwives report moral distress when they cannot deliver the standard of care they were trained to provide. One midwife in Eastern Highlands Province described using cold tea leaves as uterine packing, a traditional remedy she had never been taught but felt compelled to try.

Staff turnover is higher in facilities with chronic stockouts. A 2024 survey by the Papua New Guinea Midwifery Society found that 60% of midwives in rural posts had considered leaving within the past year, citing lack of essential supplies as a primary reason. No formal debriefing exists after near-miss events, leaving clinicians to process trauma alone.

The constant improvisation also affects clinical judgment. When every hemorrhage becomes a crisis, midwives may overuse interventions like manual removal of the placenta, increasing infection risk. Some develop a reflexive reliance on transfer, even when transport is unavailable, creating a sense of helplessness that erodes confidence.

Burnout is compounded by isolation. Rural midwives often work alone or with a single assistant. They have no colleague to consult during a crisis. A 2022 qualitative study published in Rural and Remote Health interviewed 20 midwives in Papua New Guinea and found that many reported symptoms of post-traumatic stress after PPH events. One participant said, 'I cried for three days after that mother died. I knew I could have saved her if I had the drug.'

The psychological impact extends to personal life. Midwives in remote posts often live in staff housing adjacent to the clinic. They are on call 24 hours a day, seven days a week. The boundary between work and home dissolves. Several midwives in the study said they had considered leaving the profession entirely, not just their current post.

Some facilities have started informal peer support networks using mobile phones. Midwives in neighbouring districts call each other after difficult cases. These networks are fragile—phone credit is expensive and network coverage is patchy—but they offer a lifeline. The Papua New Guinea Midwifery Society is exploring a formal debriefing programme, but funding is limited.

Community-Led Alternatives Fill the Void

In response to persistent stockouts, some districts have developed local solutions. Health extension workers teach families to recognize bleeding signs—soaking more than one cloth per hour—and to seek care immediately. Traditional birth attendants, who attend roughly half of all deliveries in rural areas, receive training in referral timing and basic hemorrhage first aid.

In a pilot program in Milne Bay Province, misoprostol is distributed antenatally for self-administration after home births. Early results suggest reduced PPH-related deaths, though concerns about misuse and delayed facility care remain. The National Department of Health has also piloted mobile stock alerts, where midwives text supply levels to a central database, but coverage remains patchy.

Local supply chains now use motorbike couriers for emergency restock in some districts, cutting delivery time from weeks to hours. These ad hoc networks are fragile—dependent on fuel availability and road conditions—but they represent a pragmatic adaptation that central procurement has not matched.

Another community-led innovation is the use of non-pneumatic anti-shock garments (NASGs). These are simple neoprene suits that compress the lower body to maintain blood pressure during hemorrhage. A 2019 pilot in two provinces distributed 50 NASGs to health centres and trained midwives in their use. Early feedback was positive: midwives reported that the garments bought time for transfer or for misoprostol to take effect. However, the garments are not reusable and cost around US$ 30 each—a significant expense for a rural clinic with a small budget. Scaling up would require donor support.

Traditional birth attendants (TBAs) are another key resource. In many communities, TBAs are the first point of contact for pregnant women. Programmes in the Highlands have trained TBAs to recognise signs of hemorrhage and to administer misoprostol sublingually if a midwife is not available. A 2021 evaluation of one such programme found that TBA-administered misoprostol reduced the time to treatment by an average of 45 minutes. However, some health officials worry that empowering TBAs might undermine facility-based deliveries. The tension between community engagement and institutional care is ongoing.

The mobile stock alert system, known as mSupply, was launched in 2020 with funding from the Australian government. Midwives in pilot districts send a weekly SMS with their stock levels of oxytocin, misoprostol, and magnesium sulfate. The data is aggregated and used to trigger resupply from district warehouses. Early results showed a 25% reduction in stockout days for oxytocin in participating facilities. But the system depends on midwives having a working phone and network coverage, which is not universal. In some areas, midwives must walk to a hilltop to get a signal. Scaling mSupply to all 600 facilities would require investment in infrastructure and training.

What Primary Care Can Learn from the Pacific

The oxytocin gap in Papua New Guinea is not an isolated story. Recent news highlights similar fragility elsewhere: French colorectal screening kits reach a 40% return rate, but pathology labs process only a fraction of positives, revealing a diagnostic bottleneck. Hypertension becomes stroke in Johannesburg miners while private patients get home monitoring, illustrating how supply chains stratify outcomes by geography and income.

Even in high-income settings, drug stockouts disrupt care. The 2026 US measles outbreaks, with cases approaching last year's record total, showed encephalitis and sepsis among hospitalized patients—complications that vaccines could have prevented if supply chains had not faltered. And as Alzheimer's blood tests improve primary care diagnoses in Sweden, the question remains: what good is a diagnostic tool if the treatment is unavailable?

Every clinical setting needs a 'plan B' for essential drug stockouts. In Papua New Guinea, that plan B is being written by midwives in real time, without formal training or support. Their experience offers lessons for primary care globally: stockouts are not just a procurement problem; they are a clinical reality that training and audits must address.

A broader lesson is the importance of adaptive leadership. In Papua New Guinea, midwives at the frontline have developed workarounds that no central planner could have designed. Motorbike couriers, TBA training, and mobile alerts all emerged from local initiative. Health systems in other low-resource settings—from rural India to sub-Saharan Africa—face similar challenges. Investing in frontline problem-solving, rather than top-down solutions alone, may yield more resilient supply chains.

Another lesson is the need for realistic simulation training. In high-income countries, PPH drills often assume a fully stocked drug tray. But in many settings, that assumption is false. International guidelines should include a 'stockout scenario' as a standard component of PPH training. The WHO's Emergency Triage Assessment and Treatment (ETAT) guidelines already include a stockout module for paediatric emergencies; a similar module for obstetric emergencies is overdue.

Three Shifts to Close the Practice Gap

First, train midwives for drug-absent hemorrhage management. Every PPH simulation should include a scenario where the oxytocin vial is empty, forcing clinicians to practice bimanual compression, aortic compression, and misoprostol dosing from memory. Second, integrate supply-chain data into clinical audits. When a maternal death is reviewed, the question should not only be 'Was oxytocin given?' but 'Was oxytocin available?'

Third, fund local cold-chain solutions, not just central procurement. Solar-powered refrigerators, passive coolers, and motorbike couriers have shown promise in pilot districts, but they require sustained investment. The National Department of Health's mobile stock alert system, if scaled, could provide real-time data to prevent shortages before emergencies arise.

Finally, measure maternal outcomes by actual care received, not guidelines. A facility that reports 100% oxytocin use may simply be discarding expired stock or documenting administration without giving the drug. Outcomes—rates of severe hemorrhage, transfusion, and death—tell the true story. Papua New Guinea's midwives deserve a system that supports them, not one that leaves them improvising with cold tea leaves.

These shifts are not expensive. A solar-powered refrigerator costs roughly US$ 1,000–2,000, a fraction of the cost of a single maternal death in lost productivity and family suffering. Training modules can be integrated into existing in-service programmes at minimal marginal cost. The main barrier is political will and coordination between health, finance, and logistics ministries. Papua New Guinea's National Health Plan 2021–2030 prioritises maternal health, but implementation has been slow. Donor agencies, including the World Bank and the Australian Department of Foreign Affairs and Trade, have pledged support, but funds often get tied up in procurement delays.

In the meantime, midwives continue to improvise. They deserve recognition for their resilience, but resilience is not a substitute for reliable supply. The goal should be a system where no midwife has to face a postpartum hemorrhage with an empty shelf. Until then, every PPH simulation should include an empty vial, every audit should track availability, and every policy should start from the reality of the clinic floor.

This article is for informational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider based on local guidelines and available resources.